Westerville 575 Copeland Mill Road Suite# 2F Westerville, Ohio 43081





Lancaster 2405 Columbus Street Suite# 210

Lancaster, Ohio 43130

TYRUKO (natalizumab-sztn)	ORDER FORM Date:
PATIENT INFORMATION	
Name: Phone:	
□NKDA Allergies:	Weight lbs/kg:
PHYSICIAN INFORMATION	
Physician Name*:	Practice Name:
Address:	Office Contact Name: Office Contact #:
Phone: Fax:	Email (for updates):
REFERRAL STATUS	
□New Referral □Referral Renewal □Medication/Order Change □Benefits Verification Only □Discontinuation Order	
TYRUKO: is an integrin receptor antagonist indicated for treatment of:  Multiple Sclerosis (MS)  TYRUKO is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.  Crohn's Disease (CD)  TYRUKO is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. Important Limitations: In CD, TYRUKO should not be used in combination with immunosuppressants or inhibitors of TNF-α.	
DIAGNOSIS Please provide ICD-10 code      PRE-MEDICATION   Tylenol PO 650mg	TYRUKO ORDERS  PATIENT WEIGHT    lbs   kg  DOSAGE  300mg IV  Other  FREQUENCY  Every 4 weeks for month Other  LAST DOSAGE OF  Avonex   Betaseron   Tysabri   Date of last dose:  LAB DRAW REQUEST  Labs: Freq:
NOTE:	REQUIRED DOCUMENTATION CHECKLIST:
	Patient Demographics
	Insurance Card/Information
	Recent labs to include CBC, CMP, JCV and Hep B surface antigen and any other recent labs
	Please Confirm Provider is registered in CD or MS Tyruko REMS
	Current Medication List
WARNINGS AND PRECAUTIONS https://www.pi.amgen.com/-/media/Project/Amgen/Repositorypi-amgen-com/Riabni/riabni_pi_english.pdf	Other
ORDERING PROVIDER	
C:	Data

\_\_\_\_\_\_ Phone \_\_\_\_\_\_ Fax \_\_